March 27, 2025

FDA Approves First Hyperphagia Drug for PWS

FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.

Reuters

March 27, 2025

Trends in Spironolactone Prescribing Among Young Women

A cohort study of 38 million insured females aged 12 to 40 years found a marked increase in spironolactone prescriptions, most commonly for acne and other androgen-related conditions.

Conexiant

March 25, 2025

Microplastics: Chewing Gum May Release Particles Into Saliva

"Surprisingly, both synthetic and natural gums had similar amounts of microplastics released when we chewed them."

Conexiant

March 24, 2025

Longer Breastfeeding Duration Linked to Fewer Developmental Delays in Large Study

Children breastfed for 6+ months showed 27% lower odds of developmental delays and neurodevelopmental conditions in comprehensive Israeli analysis of 570,000+ children, with sibling comparisons confirming protective effects.

Conexiant

March 20, 2025

Prenatal Exposure to PFAS in Contaminated Water

Results suggest associations between predicted prenatal maternal PFAS serum concentrations and some childhood cancers

Conexiant

March 18, 2025

FDA Approves First Liquid Losartan Formulation

FDA approves Arbli (TM), the first ready-to-use losartan oral suspension for hypertension, stroke risk reduction, and diabetic nephropathy.

Conexiant

March 14, 2025

FDA Warns of Nitrous Oxide Misuse

The FDA warns of serious health risks associated with non-medical use of nitrous oxide, highlighting neurological damage, thromboembolic events, and death.

Reuters

March 14, 2025

Oral Male Contraceptive Shows Promise

New nonhormonal compound YCT-529 effectively and reversibly inhibits fertility in mice and nonhuman primates, and may offer potential breakthrough in male birth control options

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters